Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
12 December 2023 |
Main ID: |
EUCTR2018-004614-18-PL |
Date of registration:
|
09/07/2019 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Active Crohn's Disease
|
Scientific title:
|
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease - VIVID-1 |
Date of first enrolment:
|
03/09/2019 |
Target sample size:
|
1150 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004614-18 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: yes Other specify the comparator: Ustekinumab Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Canada
|
China
|
Croatia
|
Czech Republic
|
Czechia
|
Denmark
|
France
|
Germany
|
Hungary
|
India
|
Israel
|
Italy
|
Japan
|
Korea, Republic of
|
Latvia
|
Lithuania
|
Malaysia
|
Mexico
|
Netherlands
|
Poland
|
Romania
|
Russian Federation
|
Serbia
|
Slovakia
|
Spain
|
Sweden
|
Switzerland
|
Taiwan
|
Turkey
|
Ukraine
|
United Kingdom
|
United States
| | | |
Contacts
|
Name:
|
Clinical Trial Registry Office
|
Address:
|
Lilly Corporate Center, DC 1526
IN 46285
Indianapolis
United States |
Telephone:
|
|
Email:
|
EU_Lilly_Clinical_Trials@lilly.com |
Affiliation:
|
Eli Lilly |
|
Name:
|
Clinical Trial Registry Office
|
Address:
|
Lilly Corporate Center, DC 1526
IN 46285
Indianapolis
United States |
Telephone:
|
|
Email:
|
EU_Lilly_Clinical_Trials@lilly.com |
Affiliation:
|
Eli Lilly |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: • Diagnosis of CD for at least 3 months prior to baseline • Confirmed diagnosis of moderate to severe CD as assessed by SF, AP score, and SES-CD • Demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD • If female, subject must meet the contraception recommendations Are the trial subjects under 18? yes Number of subjects for this age range: 50 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1045 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 55
Exclusion criteria: • Have a current diagnosis of ulcerative colitis or inflammatory bowel disease-unclassified (formerly known as indeterminate colitis). • Currently have or are suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained, adequately treated and resolved at least 3 weeks prior to baseline or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery. • Have a stoma, ileoanal pouch or ostomy. • Have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline • Have ever received anti-IL-23p19 antibodies
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
|
moderately to severely active Crohn’s disease MedDRA version: 20.0
Level: PT
Classification code 10011401
Term: Crohn's disease
System Organ Class: 10017947 - Gastrointestinal disorders
|
Intervention(s)
|
Product Name: MIRIKIZUMAB Product Code: LY3074828 Pharmaceutical Form: Solution for injection INN or Proposed INN: MIRIKIZUMAB CAS Number: 1884201-71-1 Current Sponsor code: LY3074828 Other descriptive name: MIRIKIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use
Product Name: MIRIKIZUMAB Product Code: LY3074828 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Mirikizumab CAS Number: 1884201-71-1 Current Sponsor code: LY3074828 Other descriptive name: MIRIKIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
Trade Name: STELARA 130 mg concentrate for solution for infusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: USTEKINUMAB CAS Number: 815610-63-0 Other descriptive name: USTEKINUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
Trade Name: Stelara 90 mg solution for injection in pre-filled syringe Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: USTEKINUMAB CAS Number: 815610-63-0 Other descriptive name: USTEKINUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use
Product Name: MIRIKIZUMAB Product
|
Primary Outcome(s)
|
Main Objective: To evaluate the efficacy of mirikizumab is superior to placebo in participants with Crohn's disease as assessed by - clinical response by patient reported outcome (PRO) at Week 12 and endoscopic response at Week 52 - clinical response by patient reported outcome (PRO) at Week 12 and clinical remission by Crohn's Disease Activity Index (CDAI) at Week 52
|
Primary end point(s): 1. Percentage of Participants Achieving Clinical Response and Endoscopic Response Clinical response by Patient Reported Outcome (PRO) based on stool frequency (SF) and abdominal pain (AP) Endoscopic response based on Simple Endoscopic Score for Crohn's Disease (SES-CD) total score 2. Percentage of Participants Achieving Clinical Response and Clinical Remission Clinical response by PRO based on SF and AP Clinical remission based on CDAI
|
Secondary Objective: - To evaluate the efficacy of mirikizumab is superior to placebo as assessed by endoscopic response, endoscopic remission, clinical remission by CDAI, and Urgency NRS - To evaluate the efficacy of mirikizumab in comparison to ustekinumab as assessed by endoscopic response, endoscopic remission, clinical remission by CDAI - To evaluate the efficacy of mirikizumab in comparison to placebo in health outcomes and quality of life measures, symptomatic endpoints, inflammatory biomarkers - To evaluate the pharmacokinetic and pharmacokinetic/pharmacodynamic relationships of mirikizumab
|
Timepoint(s) of evaluation of this end point: Week 12, Week 52
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: secondary endpoint [3 ,4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17] Timepoints: Week 52 secondary endpoint [5 ,6, 7, 8, 9, 10, 11, 14, 15] Timepoints: Week 12 secondary endpoint [11] Timepoints: Week 40-52
|
Secondary end point(s): 3. Proportion of participants achieving endoscopic response based on Simple Endoscopic Score for Crohn's Disease (SES-CD) total score 4. Proportion of participants achieving clinical remission by CDAI 5. Proportion of participants achieving endoscopic response based on SES-CD total score 6. Proportion of participants achieving endoscopic remission based on SES-CD total score 7. Percentage of Participants achieving clinical remission based on CDAI 8. Change from baseline in Urgency NRS 9. Percentage of Participants Achieving Clinical Response and Clinical Remission based on PRO 10. Percentage of Participants Achieving Clinical Response by PRO and Endoscopic Remission by SES-CD 11. Percentage of Participants Who Are Corticosteroid-free AND in Clinical Response by PRO AND either in Clinical Remission by CDAI or Endoscopic Remission by SES-CD 12. Change from Baseline in C-Reactive Protein 13. Change from Baseline in Fecal Calprotectin 14. Percentage of Participants Achieving Clinical Response by PRO with Extraintestinal Manifestations (EIMs) of Crohn's Disease 15. Percentage of participants achieving clinical response by PRO with fistulae response 16. Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Mirikizumab 17. Change from Baseline in Health Related Quality of Life based on Inflammatory Bowel Disease Questionnaire (IBDQ) score
|
Secondary ID(s)
|
I6T-MC-AMAM
|
2018-004614-18-AT
|
Source(s) of Monetary Support
|
Eli Lilly and Company
|
Ethics review
|
Status: Approved
Approval date: 08/08/2019
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|